Personalized blood thinner plan after stent placement
Part of Heart & circulation clinical trials.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart procedure called PCI with placement of a drug-eluting stent (DES)
- You are 18 years or older
- You can sign consent before any study-specific tests or procedures
- You do NOT have a planned staged PCI (no more planned PCI treatments soon after this one)
- You do NOT need long-term oral anticoagulation (another type of blood thinner)
- You are not allergic to aspirin or the “P2Y12” medicines (clopidogrel, ticagrelor, prasugrel)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
This trial is testing a way to shorten the time you need to take blood thinners after getting a specific type of heart stent. It uses a special camera (OCT) inside the artery to help decide if stents are placed well enough to allow less time on dual antiplatelet therapy.
This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
This trial compares 12 months versus 24 months of dual antiplatelet therapy (two blood thinners) after a stent placement in people with high lipoprotein(a) levels. It aims to see if longer treatment reduces heart risks without increasing bleeding.
Hear when a new Percutaneous Coronary Intervention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.